We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preclinical targeting of liver fibrosis with a <sup>89</sup> Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β.
- Authors
Muns, Joey A; Schooten, Erik; van Dasselaar, Rychon D J; Noordman, Yvet E; Adamzek, Kevin; Eibergen, Arthur C; Pronk, Sebas D; Cali, Sagel; Sijbrandi, Niels J; Merkul, Eugen; Oliveira, Sabrina; van Bergen En Henegouwen, Paul M P; Takkenberg, R Bart; Verheij, Joanne; van de Graaf, Stan F J; Nijmeijer, Bart A; van Dongen, Guus A M S
- Abstract
Hepatic fibrosis develops as a response to chronic liver injury, resulting in the formation of fibrous scars. This process is initiated and driven by collagen-producing activated myofibroblasts which reportedly express high levels of platelet derived growth factor receptor-β (PDGFRβ). We therefore regard PDGFRβ as an anchor for diagnosis and therapy. The Fibrobody® SP02SP26-ABD is a biparatopic VHH-construct targeting PDGFRβ. Here, we explore its potential as a theranostic vector for liver fibrosis.
- Publication
European journal of nuclear medicine and molecular imaging, 2024, Vol 51, Issue 12, p3545
- ISSN
1619-7089
- Publication type
Journal Article
- DOI
10.1007/s00259-024-06785-9